Literature DB >> 10753190

Development of a syngeneic mouse model for events related to ovarian cancer.

K F Roby1, C C Taylor, J P Sweetwood, Y Cheng, J L Pace, O Tawfik, D L Persons, P G Smith, P F Terranova.   

Abstract

Mouse ovarian surface epithelial cells (MOSEC) were obtained from virgin, mature mice by mild trypsinization and were repeatedly passaged in vitro. Early passage cells (<20 passages) exhibited a cobblestone morphology and contact inhibition of growth. After approximately 20 passages in vitro, cobblestone morphology and contact inhibition of growth was lost. Tumor forming potential was determined by s.c. and i.p. injection of early and late passage cells into athymic and syngeneic C57BL6 mice. Subcutaneous tumors formed in approximately 4 months and were present only at the injection site. Intraperitoneal injection of late passage MOSEC into athymic and syngeneic mice resulted in growth of tumor implants throughout the abdominal cavity, and production of hemorrhagic ascitic fluid. Early passage MOSEC did not form tumors in vivo. Histopathologic analysis of tumors revealed a highly malignant neoplasm containing both carcinomatous and sarcomatous components. Late passage MOSEC expressed cytokeratin and did not produce ovarian steroids in response to gonadotropin stimulation in vitro. Ten clonal lines were established from late passage MOSEC. Each clone formed multiple peritoneal tumors and ascitic fluid after i.p. injection into C57BL6 mice. Three cell lines examined cytogenetically were polyploid with near-tetraploid modal chromosome numbers. Common clonal chromosome gains and losses included +5, +15, +19 and -X, -3, -4. One cell line had a clonal translocation between chromosomes 15 and 18 and another had a small marker chromosome; common structural abnormalities were not observed. These data describe the development of a mouse model for the study of events related to ovarian cancer in humans. The ability of the MOSEC to form extensive tumors within the peritoneal cavity, similar to those seen in women with Stage III and IV cancer, and the ability of the MOSEC to produce tumors in mice with intact immune systems, makes this model unique for investigations of molecular and immune interactions in ovarian cancer development.

Entities:  

Mesh:

Year:  2000        PMID: 10753190     DOI: 10.1093/carcin/21.4.585

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  275 in total

1.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.

Authors:  Isabelle Tanjoni; Colin Walsh; Sean Uryu; Alok Tomar; Ju-Ock Nam; Ainhoa Mielgo; Ssang-Taek Lim; Congxin Liang; Marcel Koenig; Connie Sun; Neela Patel; Cheni Kwok; Gerald McMahon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

3.  Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models.

Authors:  Robert Clark; Venkatesh Krishnan; Michael Schoof; Irving Rodriguez; Betty Theriault; Marina Chekmareva; Carrie Rinker-Schaeffer
Journal:  Am J Pathol       Date:  2013-08       Impact factor: 4.307

4.  Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.

Authors:  Juan R Cubillos-Ruiz; Jason R Baird; Amelia J Tesone; Melanie R Rutkowski; Uciane K Scarlett; Ana L Camposeco-Jacobs; Jorge Anadon-Arnillas; Noah M Harwood; Murray Korc; Steven N Fiering; Lorenzo F Sempere; Jose R Conejo-Garcia
Journal:  Cancer Res       Date:  2012-02-03       Impact factor: 12.701

5.  Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing.

Authors:  Donald M Lamkin; Susan K Lutgendorf; David Lubaroff; Anil K Sood; Terry G Beltz; Alan Kim Johnson
Journal:  Brain Behav Immun       Date:  2010-12-21       Impact factor: 7.217

6.  Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling.

Authors:  Aaron J Grossberg; Elisabeth G Vichaya; Diana L Christian; Jessica M Molkentine; Daniel W Vermeer; Phillip S Gross; Paola D Vermeer; John H Lee; Robert Dantzer
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

7.  Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Authors:  Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter
Journal:  Oncoimmunology       Date:  2018-02-16       Impact factor: 8.110

8.  Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Authors:  Nikolaos Svoronos; Alfredo Perales-Puchalt; Michael J Allegrezza; Melanie R Rutkowski; Kyle K Payne; Amelia J Tesone; Jenny M Nguyen; Tyler J Curiel; Mark G Cadungog; Sunil Singhal; Evgeniy B Eruslanov; Paul Zhang; Julia Tchou; Rugang Zhang; Jose R Conejo-Garcia
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

9.  Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

Authors:  Aaron M Miller; Milad Bahmanof; Dietmar Zehn; Ezra E W Cohen; Stephen P Schoenberger
Journal:  Cancer Immunol Res       Date:  2018-11-27       Impact factor: 11.151

10.  Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

Authors:  Shawna L Bull Phelps; Juliet Carbon; Andrew Miller; Emely Castro-Rivera; Shanna Arnold; Rolf A Brekken; Jayanthi S Lea
Journal:  Am J Obstet Gynecol       Date:  2008-11-06       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.